Low LDL and Cancer Risk: Vytorin?

FDA has rejected cancer scare associated with Vyotorin.Meanwhile, the WSJ reports, the House Energy and Commerce Committee sent more letters to Merck and Schering yesterday. The committee wants to see the analysis of the SEAS trial conducted by an outside expert who concluded that the trial’s cancer findings were an anomaly, and the drug doesn’t increase cancer risk. Association of Low LDL with increasing incidence of cancer has been reported.This study says previously reported association of low levels of on-treatment LDL-C and incident cancer, confirmed here, is not driven by statins, and statin therapy, despite producing marked reductions in LDL-C, is not associated with an increased risk of cancer. Further studies are needed to validate these findings, particularly with longer durations of follow-up. Read more..